Metraipolis › archive › dc_b945642caa3d
Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy — Europe PMC PMID:41250091
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41250091
- DOI
- 10.1186/s12943-[numero omesso]-9
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T11:58:09.369Z
- SHA-256 of the archived text
ecbdc15104c7806c0c242e237750844a0d8295d92f7de184e08c94b9fb797760- Stable URL of this page
https://metraipolis.com/documento/dc_b945642caa3d
How to cite
Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy — Europe PMC PMID:41250091 — Europe PMC (en), https://europepmc.org/article/MED/41250091 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b945642caa3d (Metraipolis archive dc_b945642caa3d, sha256 ecbdc15104c7806c0c242e237750844a0d8295d92f7de184e08c94b9fb797760)
BibTeX
@misc{dcb945642caa3d,
title = {Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy — Europe PMC PMID:41250091},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41250091},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b945642caa3d; sha256 ecbdc15104c7806c0c242e237750844a0d8295d92f7de184e08c94b9fb797760},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41250091. Agents can read the archived copy with the MCP tool read_document.